Mylan NV
Find Ratings ReportsMYLAN NV's gross profit margin for the second quarter of its fiscal year 2017 is essentially unchanged when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. MYLAN NV has weak liquidity. Currently, the Quick Ratio is 0.74 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
During the same period, stockholders' equity ("net worth") has increased by 24.23% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
| Income Statement | Q2 FY17 | Q2 FY16 |
|---|---|---|
| Net Sales ($mil) | 2962.2 | 2560.7 |
| EBITDA ($mil) | 905.8 | 787.7 |
| EBIT ($mil) | 497.6 | 484.3 |
| Net Income ($mil) | 297.0 | 168.4 |
| Balance Sheet | Q2 FY17 | Q2 FY16 |
|---|---|---|
| Cash & Equiv. ($mil) | 876.3 | 6518.0 |
| Total Assets ($mil) | 35506.2 | 28836.3 |
| Total Debt ($mil) | 14989.9 | 13483.4 |
| Equity ($mil) | 12832.9 | 10329.9 |
| Profitability | Q2 FY17 | Q2 FY16 |
|---|---|---|
| Gross Profit Margin | 56.23 | 58.53 |
| EBITDA Margin | 30.57 | 30.76 |
| Operating Margin | 16.8 | 18.91 |
| Sales Turnover | 0.34 | 0.34 |
| Return on Assets | 1.86 | 2.79 |
| Return on Equity | 5.15 | 7.79 |
| Debt | Q2 FY17 | Q2 FY16 |
|---|---|---|
| Current Ratio | 1.35 | 3.23 |
| Debt/Capital | 0.54 | 0.57 |
| Interest Expense | 128.0 | 54.4 |
| Interest Coverage | 3.89 | 8.9 |
| Share Data | Q2 FY17 | Q2 FY16 |
|---|---|---|
| Shares outstanding (mil) | 536.12 | 508.42 |
| Div / share | 0.0 | 0.0 |
| EPS | 0.55 | 0.33 |
| Book value / share | 23.94 | 20.32 |
| Institutional Own % | n/a | n/a |
| Avg Daily Volume | 5853664.0 | 5936264.0 |
HOLD. The current P/E ratio indicates a discount compared to an average of 28.08 for the Pharmaceuticals industry and a premium compared to the S&P 500 average of 24.31. For additional comparison, its price-to-book ratio of 1.35 indicates a significant discount versus the S&P 500 average of 3.03 and a significant discount versus the industry average of 16.44. The price-to-sales ratio is well below both the S&P 500 average and the industry average, indicating a discount. Upon assessment of these and other key valuation criteria, MYLAN NV proves to trade at a discount to investment alternatives within the industry.
| Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MYL 26.47 | Peers 28.08 | MYL 6.80 | Peers 25.61 | |||||||||||||||||||||
|
Average. An average P/E ratio can signify an industry neutral price for a stock and an average growth expectation. MYL is trading at a valuation on par with its peers. |
Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. MYL is trading at a significant discount to its peers. |
|||||||||||||||||||||||
| Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
| MYL 6.18 | Peers 14.98 | MYL 0.07 | Peers 0.61 | |||||||||||||||||||||
|
Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations. MYL is trading at a significant discount to its peers. |
Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. MYL trades at a significant discount to its peers. |
|||||||||||||||||||||||
| Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
| MYL 1.35 | Peers 16.44 | MYL -22.30 | Peers 25.27 | |||||||||||||||||||||
|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. MYL is trading at a significant discount to its peers. |
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. However, MYL is expected to significantly trail its peers on the basis of its earnings growth rate. |
|||||||||||||||||||||||
| Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
| MYL 1.44 | Peers 6.45 | MYL 20.81 | Peers 8.29 | |||||||||||||||||||||
|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. MYL is trading at a significant discount to its industry on this measurement. |
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share. MYL has a sales growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
